Clinical bottom line
Pediatric sudden onset sensorineural hearing loss (SSNHL) with suspected autoimmune etiology remains a diagnostic and therapeutic challenge. Emerging evidence supports consideration of autoimmune mechanisms in a subset of pediatric SSNHL cases, prompting tailored immunomodulatory treatment strategies beyond standard corticosteroids. However, definitive diagnostic biomarkers and consensus management protocols are lacking, and the evidence base is limited by small cohorts and heterogeneous methodologies. Clinicians should maintain a high index of suspicion for autoimmune causes in pediatric SSNHL, especially in cases refractory to conventional therapy or with systemic autoimmune features, while balancing risks and benefits of immunosuppressive interventions.
What the evidence shows
Sudden sensorineural hearing loss in children is rare but can have significant long-term consequences. Hanson et al. (2026) highlight that pediatric SSNHL differs from adult presentations in etiology and response to treatment, with autoimmune processes increasingly recognized as contributory in some cases. García Berrocal et al. (2024) provide a detailed review of the autoimmune hypothesis, describing mechanisms such as antibody-mediated inner ear damage and T-cell–driven inflammation. They emphasize that autoimmune inner ear disease (AIED) may present acutely or subacutely with bilateral or unilateral hearing loss, often accompanied by systemic autoimmune markers or comorbidities.
Diagnostic workup incorporating serologic testing for autoimmune markers, imaging with MRI to exclude alternative causes (Herrera et al., 2024), and clinical correlation is recommended but not standardized. Lambert et al. (2018) note that MRI can help exclude retrocochlear pathology and identify inflammatory changes, although findings specific to autoimmune SSNHL are not definitive.
Therapeutically, corticosteroids remain first-line, but García Berrocal et al. (2024) and Hanson et al. (2026) discuss adjunctive immunosuppressive agents such as methotrexate or biologics in refractory or relapsing cases, extrapolating from adult data and autoimmune inner ear disease literature. Goswami et al. (2026) report a case linking latent autoimmune diabetes in adults with SSNHL, underscoring the potential overlap of systemic autoimmune conditions and hearing loss, which may inform pediatric considerations.
Practice surveys (Luu et al., 2023) reveal variability in diagnostic and treatment approaches, reflecting uncertainty and the need for consensus guidelines. Dedhia et al. (2016) reported on 20 pediatric SSNHL cases, noting autoimmune etiology in a minority but stressing the importance of early recognition and treatment to improve outcomes.
Caveats and uncertainty
The evidence base for autoimmune pediatric SSNHL is limited by small sample sizes, retrospective designs, and lack of randomized controlled trials. Biomarkers for autoimmune inner ear disease lack sensitivity and specificity, complicating diagnosis. Imaging findings are often nonspecific, and overlap with viral, vascular, or idiopathic causes is common (Herrera et al., 2024; García Berrocal et al., 2024).
Treatment recommendations largely derive from adult studies or case series, with pediatric-specific data sparse. The risk-benefit profile of immunosuppressive therapies in children requires careful consideration, given potential adverse effects and the variable natural history of SSNHL.
Heterogeneity in clinical presentation and response to therapy further complicates establishing standardized protocols. The temporal relationship between systemic autoimmune diseases and SSNHL onset in children is not well defined, limiting predictive capacity.
How this may change practice
Clinicians managing pediatric SSNHL should consider autoimmune etiologies in differential diagnosis, particularly in cases with bilateral involvement, systemic autoimmune symptoms, or poor response to corticosteroids. Early multidisciplinary evaluation including rheumatology may be warranted.
Incorporating targeted serologic testing and MRI can aid in excluding alternative diagnoses and supporting autoimmune suspicion, though negative results do not exclude the diagnosis. Awareness of emerging immunomodulatory therapies may expand treatment options for refractory cases, but such interventions should be reserved for carefully selected patients within specialist settings.
Ongoing research and consensus development are needed to refine diagnostic criteria, validate biomarkers, and establish evidence-based treatment algorithms tailored to pediatric populations. Meanwhile, individualized patient assessment and shared decision-making remain paramount.